兼具醫美和疫苗概念 復星醫藥(2196.HK)持續拉昇再創歷史新高
格隆匯5月4日丨同時兼具醫美和疫苗兩大熱門概念的復星醫藥(2196.HK)近期持續走強,在昨日創出歷史新高價後,今日盤中繼續拉昇,一度漲近6%報62.5港元,再創歷史新高價,市值超1800億港元。該股年內累計漲幅接近70%。醫美方面,去年10月,落户重慶的星榮整形外科醫院完成開業盛典,成為復星首個醫美旗艦院。疫苗方面,復星醫藥獲BioNTech授權在中國大陸及港澳台獨家開發、商業化mRNA新冠疫苗。目前mRNA新冠疫苗BNT162b2“復必泰”已被使用在香港、澳門的政府接種計劃,國內有望二季度獲批。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.